115 related articles for article (PubMed ID: 38486129)
1. Comments on "Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region".
Goel A; Kapatia G; Gupta S; Gupta V; Sidana S
Diagn Cytopathol; 2024 May; 52(5):288-289. PubMed ID: 38486129
[No Abstract] [Full Text] [Related]
2. Respond to "Comments on 'Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda category III in an endemic region'".
Aydın Kasap Z; Kurt B; Özsağır E; Ercin ME; Güner A
Diagn Cytopathol; 2024 May; 52(5):290-291. PubMed ID: 38504597
[No Abstract] [Full Text] [Related]
3. Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
Yoo MR; Gweon HM; Park AY; Cho KE; Kim JA; Youk JH; Son EJ
PLoS One; 2015; 10(6):e0130138. PubMed ID: 26115096
[TBL] [Abstract][Full Text] [Related]
4. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
5. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Bethesda System and the ACR TIRADS in an Endemic Goiter Region.
Karaagac M; Sarigoz T; Ertan T; Topuz O
Endocr Res; 2020 Nov; 45(4):226-232. PubMed ID: 32729365
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of sonographic features in indeterminate pediatric thyroid nodules.
Richman DM; Cherella CE; Smith JR; Modi BP; Zendejas B; Frates MC; Wassner AJ
Eur J Endocrinol; 2021 May; 184(5):657-665. PubMed ID: 33635830
[TBL] [Abstract][Full Text] [Related]
8. Improving Malignancy Prediction in AUS/FLUS Pediatric Thyroid Nodules with the Aid of Ultrasound.
Arora S; Khoury J; Trout AT; Chuang J
Horm Res Paediatr; 2020; 93(4):239-244. PubMed ID: 32894855
[TBL] [Abstract][Full Text] [Related]
9. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory.
Rosario PW
Thyroid; 2014 Jul; 24(7):1115-20. PubMed ID: 24684285
[TBL] [Abstract][Full Text] [Related]
10. [Thyroid nodules in children: risk of malignancy for each Bethesda category].
Varela MF; Udaquiola J; Vagni R; Jaén A; Alonso G; Moldes JM; Lobos P; Liberto D
Cir Pediatr; 2019 Jul; 32(3):135-140. PubMed ID: 31486305
[TBL] [Abstract][Full Text] [Related]
11. Malignancy outcomes and the impact of repeat fine needle aspiration of thyroid nodules with Bethesda category III cytology: A multicenter experience.
Köseoğlu D; Özdemir Başer Ö; Çetin Z
Diagn Cytopathol; 2021 Oct; 49(10):1110-1115. PubMed ID: 34196509
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound is helpful to differentiate Bethesda class III thyroid nodules: A PRISMA-compliant systematic review and meta-analysis.
Gao LY; Wang Y; Jiang YX; Yang X; Liu RY; Xi XH; Zhu SL; Zhao RN; Lai XJ; Zhang XY; Zhang B
Medicine (Baltimore); 2017 Apr; 96(16):e6564. PubMed ID: 28422844
[TBL] [Abstract][Full Text] [Related]
13. An innovative synthetic support for immunocytochemical assessment of cytologically indeterminate (Bethesda III) thyroid nodules.
Taccogna S; Papini E; Novizio R; D'Angelo M; Turrini L; Persichetti A; Pontecorvi A; Guglielmi R
Front Endocrinol (Lausanne); 2022; 13():1078019. PubMed ID: 36531453
[TBL] [Abstract][Full Text] [Related]
14. The 5-tiered categorization system for reporting cytology is sufficient for management of patients with thyroid nodules compared to the 6-tiered Bethesda system.
Koh J; Moon HJ; Kim EK; Kwak JY; Yoon JH
Endocrine; 2016 Aug; 53(2):489-96. PubMed ID: 26758996
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Lobectomy for Bethesda III Thyroid Nodules: Pathological Outcomes and Risk Factors for Malignancy.
Walters BK; Garrett SL; Aden JK; Williams GM; Butler-Garcia SL; Newberry TR; Mckinlay AJ
Ann Otol Rhinol Laryngol; 2021 Sep; 130(9):1064-1068. PubMed ID: 33567896
[TBL] [Abstract][Full Text] [Related]
16. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of fine needle aspiration cytology in pediatric thyroid nodules based on Bethesda Classification.
Jiang W; Phillips SA; Newbury RO; Naheedy JH; Newfield RS
J Pediatr Endocrinol Metab; 2021 Apr; 34(4):449-455. PubMed ID: 33629571
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic models for predicting malignancy in thyroid nodules classified as Bethesda Category III in an endemic region.
Kasap ZA; Kurt B; Özsağır E; Ercin ME; Güner A
Diagn Cytopathol; 2024 Apr; 52(4):200-210. PubMed ID: 38269646
[TBL] [Abstract][Full Text] [Related]
19. Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III.
Mileva M; Stoilovska B; Jovanovska A; Ugrinska A; Petrushevska G; Kostadinova-Kunovska S; Miladinova D; Majstorov V
Radiol Oncol; 2018 Sep; 52(4):370-376. PubMed ID: 30265655
[TBL] [Abstract][Full Text] [Related]
20. Tumor Growth Rate Does Not Predict Malignancy in Surgically Resected Thyroid Nodules Classified as Bethesda Category III with Architectural Atypia.
Kim M; Jeon MJ; Han M; Lee JH; Song DE; Baek JH; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2019 Feb; 29(2):216-221. PubMed ID: 30421654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
